(Q41532842)

2 October 2017

1 reference

title

Bryostatin 1: differentiating agent from the depths (English)

1 reference

2 October 2017

1 reference

ChEBI release 2020-05-28

Stone RM

1

1 reference

2 October 2017

publication date

1 May 1997

1 reference

2 October 2017

1 reference

2 October 2017

volume

21

1 reference

2 October 2017

issue

5

1 reference

2 October 2017

page(s)

399-401

1 reference

Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine

2 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

13-cis retinoic acid treatment for myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

Isolation and structure of bryostatin 1

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

A phase I study of intravenous bryostatin 1 in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2896%2900123-3

7 January 2021

10.1016/S0145-2126(96)00123-3

Identifiers

DOI

1 reference

2 October 2017

1 reference